RESEARCH ARTICLE

Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry [version 1; peer review: 2 approved]

Milena Music^{1*}, Marco Iafolla^{2*}, Antoninus Soosaipillai³, Ihor Batruch³, Ioannis Prassas^{id}³, Melania Pintilie⁴, Aaron R. Hansen², Philippe L. Bedard², Stephanie Lheureux², Anna Spreafico², Albiruni Abdul Razak², Lillian L. Siu², Eleftherios P. Diamandis^{id}^{1,3,5,6}

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

²Division of Medical Oncology and Hematology, University Health Network, Canada, Toronto, ON, Canada

³Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Toronto, ON, Canada

⁴Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Canada, Toronto, ON, Canada

⁵Department of Clinical Biochemistry, University Health Network, Canada, Toronto, ON, Canada

⁶Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Toronto, ON, Canada

* Equal contributors

V1 First published: 07 May 2020, 9:337
<https://doi.org/10.12688/f1000research.22715.1>
 Latest published: 07 May 2020, 9:337
<https://doi.org/10.12688/f1000research.22715.1>

Abstract

Background: Validated biomarkers are needed to identify patients at increased risk of immune-related adverse events (irAEs) to immune checkpoint blockade (ICB). Antibodies directed against endogenous antigens can change after exposure to ICB.

Methods: Patients with different solid tumors stratified into cohorts received pembrolizumab every 3 weeks in a Phase II trial (INSPIRE study). Blood samples were collected prior to first pembrolizumab exposure (baseline) and approximately 7 weeks (pre-cycle 3) into treatment. In a discovery analysis, autoantibody target immuno-mass spectrometry was performed in baseline and pre-cycle 3 pooled sera of 24 INSPIRE patients based on clinical benefit (CBR) and irAEs.

Results: Thyroglobulin (Tg) and thyroid peroxidase (TPO) were identified as the candidate autoantibody targets. In the overall cohort of 78 patients, the frequency of CBR and irAEs from pembrolizumab was 31% and 24%, respectively. Patients with an anti-Tg titer increase $\geq 1.5x$ from baseline to pre-cycle 3 were more likely to have irAEs relative to patients without this increase in unadjusted, cohort adjusted, and multivariable models (OR=17.4, 95% CI 1.8–173.8, $p=0.015$). Similarly, patients with an anti-TPO titer $\geq 1.5x$ from baseline to pre-cycle 3 were more likely to have irAEs relative to patients without the increase in unadjusted and cohort adjusted (OR=6.1, 95% CI 1.1–32.7, $p=0.035$) models. Further, the cohort

Open Peer Review

Approval Status

	1	2
version 1
07 May 2020	view	view
<hr/>		
1. Gerasimos Sykiotis	Lausanne University Hospital & University of Lausanne, Lausanne, Switzerland	
2. Francesco Salvatore	Biotechnologie Avanzate s.c.ar.l., Naples, Italy	
Domenico Salvatore	University of Naples Federico II, Naples, Italy	
Porcelli Tommaso	University of Naples Federico II, Naples, Italy	

Any reports and responses or comments on the article can be found at the end of the article.

adjusted analysis showed patients with anti-Tg titer greater than median (10.0 IU/mL) at pre-cycle 3 were more likely to have irAEs (OR=4.7, 95% CI 1.2–17.8, $p=0.024$). Patients with pre-cycle 3 anti-TPO titers greater than median (10.0 IU/mL) had a significant difference in overall survival (23.8 vs 11.5 months; HR=1.8, 95% CI 1.0–3.2, $p=0.05$).

Conclusions: Patient increase $\geq 1.5\times$ of anti-Tg and anti-TPO titers from baseline to pre-cycle 3 were associated with irAEs from pembrolizumab, and patients with elevated pre-cycle 3 anti-TPO titers had an improvement in overall survival.

Keywords

programmed cell death protein 1, immune checkpoint blockade, pembrolizumab, response, predictive biomarkers, autoantibodies, anti-thyroglobulin antibody, anti-thyroid peroxidase antibody, hypothyroidism, immune-related adverse events

Corresponding author: Eleftherios P. Diamandis (Eleftherios.diamandis@sinahealth.ca)

Author roles: **Music M:** Data Curation, Formal Analysis, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Iafolla M:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Soosaipillai A:** Data Curation, Methodology, Resources; **Batrach I:** Data Curation, Methodology, Software, Validation; **Prassas I:** Conceptualization, Data Curation, Software, Writing – Review & Editing; **Pintilie M:** Data Curation, Software, Writing – Review & Editing; **Hansen AR:** Data Curation, Investigation, Writing – Review & Editing; **Bedard PL:** Data Curation, Validation, Writing – Review & Editing; **Lheureux S:** Data Curation, Validation, Writing – Review & Editing; **Spreafico A:** Data Curation, Validation, Writing – Review & Editing; **Razak AA:** Data Curation, Validation, Writing – Review & Editing; **Siu LL:** Conceptualization, Formal Analysis, Investigation, Resources, Supervision, Writing – Review & Editing; **Diamandis EP:** Conceptualization, Methodology, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: MM, AS, IB, IP and MP have no competing interests. MI has Honoraria with Merck and CompassMD. ARH has conducted advisory/consulting/research for Genentech/Roche, Merck, GSK, Bristol-Myers Squibb, Novartis, Boston Biomedical, Boehringer-Ingelheim, AstraZeneca, Medimmune. PLB has conducted research for Bristol-Myers Squibb, Sanofi, AstraZeneca, Genentech/Roche, SERVIER, GlaxoSmithKline, Novartis, SignalChem, PTC Therapeutics, Nektar, Merck, Seattle Genetics, Mersana, Immunomedics, Lilly. SL has honoraria from AstraZeneca and Merck. AS has conducted consultancy/research for Merck, Bristol-Myers Squibb, Novartis, Oncorus, Symphogen, AstraZeneca/Medimmune, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnston & Johnston, Roche, Regeneron. AAR has honoraria and has consulted for for Boehringer Ingelheim, Lilly, Merck, CASI Pharmaceuticals, Novartis, Deciphera, Karyopharm Therapeutics, Pfizer, Roche/Genentech, Boston Biomedical, Bristol-Myers Squibb, MedImmune, Amgen, GlaxoSmithKline, Blueprint Medicines, Merck, Abbvie, Adaptimmune. LLS has conducted consulting/research for Merck, Pfizer, Celgene, AstraZeneca/Medimmune, Morphosys, Roche, GeneSeq, Loxo, Oncorus, Symphogen, Seattle Genetics, GSK, Voronoi, Novartis, Bristol-Myers Squibb, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, Astellas, Bayer, Abbvie, Amgen, Intensity Therapeutics, Mirati, Shattucksm Avid. Stock owner in Agios.

Grant information: This work was supported by the Princess Margaret Cancer Foundation. MI was supported in part by a fellowship through the BMO Chair in Precision Cancer Genomics. Merck supplied pembrolizumab as drug-only collaboration.

Copyright: © 2020 Music M *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Music M, Iafolla M, Soosaipillai A *et al.* Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry [version 1; peer review: 2 approved] F1000Research 2020, 9:337 <https://doi.org/10.12688/f1000research.22715.1>

First published: 07 May 2020, 9:337 <https://doi.org/10.12688/f1000research.22715.1>

List of abbreviations

ABC, ammonium bicarbonate; CBR, clinical benefit rate; CI, confidence intervals; CR, complete response; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; FDR, false discovery rate; HR, hazard ratios; ICB, immune checkpoint blockade; irAE, immune related adverse event; MPS, modified percent score; NSCLC, non-small cell lung cancer; OR, odds ratios; OS, overall survival; PD-1, programmed cell death protein 1; PFS, progression-free survival; PR, partial response; SD, stable disease; Tg, thyroglobulin; TPO, thyroid peroxidase.

Introduction

Despite the ability of immune checkpoint blockade (ICB) to produce enduring responses in several advanced malignancies^{1,2}, there are several limitations. Monotherapy response rates for inhibitors of programmed cell death protein-1 or its ligand (anti-PD-1/L1) across solid tumors are generally modest at approximately 20–30%, and much lower in some tumor types^{3,4}. All-grade and high-grade toxicities with PD-1/L1 approach 40% and 12%, respectively^{5–8}. Hence, there is an unmet need for predictive biomarkers to enable patient selection. Although numerous markers have already been tested for their ability to predict response to ICB¹, many require molecular and immune profiling from either invasive biopsy or archival tumor specimen⁹. Similarly, validated biomarkers that can identify patients who develop immune-related adverse events (irAEs) to ICB are lacking.

Antigen spreading is the phenomenon of *in situ* damaged cancer cells releasing intracellular antigens into the surrounding environment^{10,11}. Although tumorigenesis distorts the native structure of these antigens¹², which in turn elicit a humoral immune response that produces tumor associated antigen autoantibodies^{13–16}, several studies have investigated the biomarker potential of autoantibodies targeting wild-type proteins using large human proteome arrays in patients treated with ICB. For instance, castrate resistant prostate cancer patients responding to ipilimumab demonstrate an increase in autoantibodies targeting intracellular proteins (such as MPG, PAK6 and DLX1) relative to non-responders¹⁷. Melanoma patients who developed severe irAEs from the combination of intralesional *Bacillus Calmette-Guérin* injection and ipilimumab were found to have a significant increase in autoantibodies directed against self-antigens that preceded the clinical diagnosis of toxicity¹⁸. Pre-treatment autoantibody profiles in melanoma patients treated with anti-PD-1, anti-CTLA-4 or a combination of both agents were unique to those who developed severe irAEs¹⁹. Humoral immunity may be increased via PD-1 inhibition through direct interaction with PD-1 receptors on B-cells²⁰ and/or non-cytotoxic T-cell dependent processes²¹.

Current attempts to characterize serum autoantibodies are limited by analytic constraints inherent to complex biological samples, such as blood or lysate, that are fraught with low sensitivity^{22,23}. This study attempts to overcome this analytic limitation by typifying the serum autoantibodies using a modified version of the established Serologic Proteome Analysis assay^{24–26} that incorporates protein G purification of serum autoantibodies

and tandem mass spectrometric identification of the antibody targets.

We hypothesize that the magnitude of autoantibody production is a measure of response and/or toxicity to ICB. Our primary objective is to isolate candidate serum autoantibodies from advanced solid tumor patients receiving pembrolizumab (anti-PD-1) monotherapy on a prospective phase II clinical trial and correlate their titers with clinical outcomes.

Methods

Patients and clinical outcomes

The single-centre investigator-initiated biomarker phase II clinical trial called INSPIRE (INvestigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation; ClinicalTrials.gov ID [NCT02644369](#), registered on 31 December 2015) was designed to analyze dynamic changes in genomic, proteomic and immunologic landscapes in patients treated with pembrolizumab (anti-PD-1 antibody) monotherapy. Between March 21, 2016 to May 9, 2018, patients were prospectively enrolled into one of the following five cohorts: squamous cell cancer of the head and neck, triple negative breast cancer, epithelial ovarian cancer, malignant melanoma (cutaneous and non-cutaneous) or mixed solid tumors. Approximately 20 patients were enrolled into each cohort; the INSPIRE study was purely exploratory and no formal sample size was required. Pertinent inclusion criteria: age ≥ 18 years; ECOG 0-1; incurable histologically proven locally advanced or metastatic solid malignancy without further standard treatment options (with the exception of melanoma); measurable disease based on RECIST 1.1²⁷; and adequate organ functions. Pertinent exclusion criteria: prior anti-PD-1/L1/L2 agents (prior anti-CTLA4 and T-cell co-stimulatory agents allowed); autoimmune disease; immunodeficiency or immunosuppressive medications exceeding physiologic corticosteroid replacement; leptomeningeal disease; or < 4 weeks of stable central nervous system metastases.

All patients received monotherapy pembrolizumab (anti-PD-1 antibody) 200 mg IV every 3 weeks, were clinically assessed with comprehensive blood work every 3 weeks and received restaging CT scans every 9 weeks. Clinical benefit rate (CBR) was defined *a priori* as RECIST 1.1 complete response (CR) or partial response (PR), or stable disease (SD) for ≥ 6 cycles of pembrolizumab. Toxicity was defined *a priori* as $\geq$ Grade 2 CTCAE 4.03²⁸ irAE with at least possible attribution to pembrolizumab of which the investigator asserted the adverse event to be autoimmune in causality from pembrolizumab exposure. Grade 2 or higher grade irAEs are considered clinically significant²⁹. Only the highest grade of a specific toxicity event was recorded for each patient; the same toxicity event was recorded more than once per patient if the irAE re-occurred on a separate occasion (i.e. not a re-flare during immunosuppression taper). Both response and toxicity data were annotated by INSPIRE data coordinators and then verified by one author (MI). The causality of irAE to pembrolizumab was reviewed by MI and LLS.

The Research Ethics Board located at Princess Margaret Cancer Centre, University Health Network (Toronto, Canada) reviewed

and approved this study (#15-9828). All patients provided written informed patient consent prior to study enrollment. The study was carried out in accordance with the Declaration of Helsinki.

Sample collection and storage

Blood samples for this analysis were drawn within 28 days prior to first pembrolizumab exposure (baseline) and 7 weeks into treatment with pembrolizumab (pre-cycle 3). Upon collection of blood samples in Vacutainer® SST™ tubes, the blood was allowed to clot for 30–60 minutes, and the tubes were then centrifuged at 1,200g for 10 minutes at room temperature. In total, 500 µL of serum was aliquoted into cryogenic vials and frozen at -80°C.

Discovery analysis for candidate autoantibody identification

In order to optimize autoantibody identification, 24 patients treated on INSPIRE were selected by MI and LLS and placed into one of four groups: 6 patients without CBR or toxicity from pembrolizumab (Group I); 6 patients with toxicity but no CBR (Group II); 6 patients with both CBR and toxicity (Group III); and 6 patients with CBR but no toxicity (Group IV). To minimize bias, performance of the experiments and analysis of the results were conducted by investigators blinded to INSPIRE clinical outcomes.

In total, 12 µL of serum from each of the 6 individual patients in the four Groups (I–IV) were pooled to create mixed pools (72 µL/pool). This was done for the serum samples collected both before and after immunotherapy initiation, resulting in the following eight pooled serum samples: Group I (baseline), Group I (pre-cycle 3), Group II (baseline), Group II (pre-cycle 3), Group III (baseline), Group III (pre-cycle 3), Group IV (baseline) and Group IV (pre-cycle 3).

Human tissue lysate proteome

Human tissues were obtained from Mount Sinai Hospital (REB# 18-0077-E) and the University Health Network (REB #15-9680) at autopsy or during surgical removal. Tissue samples were stored at -80° C until ready for use. Protein was extracted from a total of 29 human body tissues and 4 human brain-specific tissues for comprehensive proteome coverage (see *Extended data*³⁰). For protein extraction, tissue was pulverized in liquid nitrogen with a mortar and pestle to yield a fine powder. Next, 0.2% RapiGest SF Surfactant (Waters, Milford, MA, USA) in 50 mM ammonium bicarbonate (ABC) was added to further lyse the tissues. The pulverized tissue sample was vortexed every 5–10 min on ice, for 30 min, and then sonicated on ice for 15 sec, three times, to further disrupt the cells. Following sonication, the sample was centrifuged at 15,000g for 20 min at 4°C, to remove debris and insoluble contents, followed by collection of the supernatant. A Pierce BCA Protein Assay (Thermo Fisher Scientific, San Jose, California) was performed on tissue lysate protein extracts for total protein quantification. Equal amounts of each tissue lysate were combined to make a 1.5-mg complex tissue lysate for each immunoprecipitation experiment.

Autoantibody immuno-mass spectrometry

Details are stated in *Extended data*³⁰. A similar method was recently validated in a proof-of-concept study that included autoantibodies to CUB and zona pellucida-like domain-containing protein 1 and

pancreatic secretory granule membrane major glycoprotein 2 in the sera of patients with inflammatory bowel disease³¹.

Selection of candidate autoantibodies

The autoantibody protein targets identified before and after pembrolizumab treatment in Groups I through IV were compared. Immunoglobulins, keratins, serum albumin and other non-specific serum-abundant proteins (such as hemoglobin), as well as complement proteins and apolipoproteins that are normally immunoprecipitated as part of immune complexes in the blood³², were excluded. The candidates were chosen based on the *a priori* definition of ≥ 2 -fold peptide number increase for the target protein from pre- to post-treatment serum in patient group II, III or IV ($n=6$ in each group) and either a ≥ 4 -fold peptide number difference compared to patient group I ($n=6$) or no identified peptides in group I¹⁷. Due to cost and feasibility, only the top candidate and a related protein candidate were further evaluated by electro-chemiluminescence immunoassay.

Electrochemiluminescence immunoassay for anti-Tg and anti-TPO antibody quantification

Immuno-mass spectrometric analysis of the discovery set showed that thyroglobulin (Tg) was the top candidate autoantibody target that met the pre-defined selection criteria. Thyroid peroxidase (TPO) was chosen as an additional candidate autoantibody target due to its known association with anti-Tg antibody in autoimmune disease. Immuno-mass spectrometric results are available as *Underlying data*³³.

All INSPIRE patients with baseline and pre-cycle 3 sera (including those used in the discovery analysis) were analyzed for the candidate autoantibody titers by electrochemiluminescence immunoassays (Elesys Anti-Tg and Elesys Anti-TPO, Roche Diagnostics, Risch-Rotkreuz, Switzerland) using a Cobas e 411 analyzer. The Cobas e 411 analyzer has an approximate 10% coefficient of variation for both anti-Tg³⁴ and anti-TPO³⁵ titers. Further, the coefficient of biological variation of these antibodies is also approximately 10%³⁶. To be conservative, a minimum 50% increase in titers from baseline to pre-cycle 3 was used to define a significant increase. Based upon instrument limitations, the measurable range of anti-TPO and anti-Tg antibodies were 5.00–600 IU/mL and 10.0–4000 IU/mL, respectively. Patients with anti-TPO titers <5.00 IU/mL and anti-Tg titers < 10.0 IU/mL were arbitrarily assigned 5.00 IU/mL and 10.0 IU/mL, respectively. One patient in the mixed solid tumor cohort had an anti-Tg titer >4000 IU/mL both at baseline and cycle 3; the value of 4000 IU/mL was used for both time points. The median value of anti-Tg titers at both baseline and pre-cycle 3 was 10.0 IU/mL (range: 10.0–4000 IU/mL) and the median value of anti-TPO titers at baseline and pre-cycle 3 was 10.10 IU/mL and 10.70 IU/mL, respectively (range: 5.00–434.70 IU/mL). For simplicity, we defined elevated anti-Tg and anti-TPO when the titer was > 10.0 IU/mL. The investigators conducting all experiments and analysis of the results were blinded to INSPIRE clinical outcomes.

Statistical analysis of candidate autoantibody targets

The co-primary endpoints were CBR and toxicity as defined above. Patients were dichotomized at baseline and pre-cycle 3 using median titers of candidate autoantibodies, and the change (Δ) in

autoantibody titer was defined as a 1.5x increase in titer from baseline to pre-cycle 3 versus stable or decrease in titer (only patients who had pre-cycle 3 titers >10.0 IU/mL were included in the Δ analysis). These groups were analyzed as predictors of CBR and toxicity. Due to the possible influence of toxicity on autoantibody production, patients who developed toxicity before the pre-cycle 3 blood draw were removed from both the CBR and toxicity pre-cycle 3 and Δ analysis. Statistical significance among the categorical variables was evaluated using Fisher's exact test. Further, the individual patient titers at baseline, pre-cycle 3, and difference in titer (defined as pre-cycle 3 titer minus baseline titer) were explored as continuous variables using the Mann-Whitney test. As with the categorical variable analysis above, patients who developed toxicity before the pre-cycle 3 blood draw were removed from both the CBR and toxicity pre-cycle 3 and difference in titer analysis.

In an effort to reduce confounding in our observational study with a small number of events, propensity scores were created based on a model incorporating age, gender, ethnicity and PD-L1 status. As outlined in the interim INSPIRE trial report³⁷, this study used formalin-fixed paraffin-embedded blocks from screening biopsies. The PD-L1 immunohistochemistry clone 22C3 was applied to 4–5 μ m sections mounted on positively charged ProbeOn slides (QualTek, Goleta, CA). QualTek produced a modified proportion score (MPS) denoting the proportion of PD-L1-expressing tumor cells and mononuclear inflammatory cells within tumor nests. Further details are found in *Extended data*³⁰. Conditional logistic regression was applied to test each candidate autoantibody and their change adjusting for strata and the propensity scores. Odds ratios (OR), their 95% confidence intervals (CI) and p-values were thus obtained.

Overall survival (OS) and progression free survival (PFS) times were calculated as the durations between the first infusion with pembrolizumab and death or progression, respectively. When death or progression were not observed the patient was considered censored. The survival percentages and median survival estimates were calculated using Kaplan-Meier method. The Hazard Ratios (HR) and their CIs were calculated within the Cox Proportional-Hazards Model. The association of toxicity with OS and PFS was analyzed using toxicity as a time-dependent covariate. The association between covariates and candidate autoantibodies were investigated using Fisher's exact test for categorical variables, or Mann-Whitney test or Spearman correlation for continuous variables (where appropriate).

All p-values were two-sided and p-values < 0.05 were considered statistically significant.

All calculations were performed using R 3.4 (The R Foundation for Statistical Computing).

Results

Patient characteristics, serum and outcomes

In total, 106 patients were enrolled into INSPIRE and 78 patients were included in this analysis. Among the excluded 28 INSPIRE patients: 2 patients had both baseline and pre-cycle 3 serum blood work but the pre-cycle 3 serum was not processed for autoantibody

quantification; 17 patients were taken off trial between cycle 2 and cycle 3; and 9 patients were taken off trial before cycle 2. Deidentified patient outcomes are available as *Underlying data*³³.

The 24 patient samples used in the discovery analysis were frozen for a median of 566 days (range 335–835 days) and thawed twice. All 78 patients used in the test set (which included the 24 patients in the discovery analysis) were frozen for a median of 626.5 days (range 257–927 days) and thawed once.

Table 1 summarizes pertinent clinicopathologic information and their association with CBR and toxicity. Gender was approximately evenly distributed (female 55%, male 45%). The median age was 61 years at time of first pembrolizumab infusion, but there was a large range in age (21–82 years). The vast majority of patients were of white ethnicity (n=64, 83%). Head and neck squamous cell carcinoma (n=14, 18%) comprised the major tumor type. Median PD-L1 MPS were 1% (range: 0 – 100%). Unadjusted univariate analysis suggested the response rate was different between the cohorts (p=0.011) and the patients who had CBR tended to have a higher percent of PD-L1 MPS in comparison to those without CBR (medians 1.5% vs 0%, p=0.029).

The CONSORT diagram in **Figure 1** depicts the relevant patient and serum sample flow through this study and clinical outcomes of each cohort. Last clinical outcome update was May 3, 2019; at that time the median follow-up was 2.35 years from date of first pembrolizumab infusion (range: 0.79–2.95 years), two patients (2.6%) were lost to follow up and 49 deaths (63%) occurred. Of the two patients lost to follow up, both developed disease progression as best response and one developed a significant toxicity event; both patients were included in the analysis. The median number of pembrolizumab infusions before coming off trial was five (range: 2–35 infusions). All patients were evaluable. CBR was achieved in 24 patients (31%): CR, PR and SD $\geq$ 6 cycles of pembrolizumab occurred in 3 patients (3.9%), 13 patients (17%) and 8 patients (10%), respectively. In total, three patients (3.9%) remained on treatment at time of analysis. RECIST disease progression (n=48, 62%) was the major reason for stopping treatment; five patients (6.4%) completed all 35 pembrolizumab cycles specified in the trial. Toxicity occurred in 19 patients (24%); hypothyroidism (n=8, 10%) was the most common toxicity, and nine patients (12%) developed more than one toxicity. Median number of days from first dose of pembrolizumab to toxicity onset was 105 (range: 1–482) and five patients (6.4%) developed toxicity before pre-cycle 3 blood draw. Toxicity necessitated stopping treatment in five patients (6.4%); of these, Grade 3 colitis (n=2, 2.6%) and Grade 3 pneumonitis (n=2, 2.6%) were the most common events. In total, seven patients (9.0%) developed Grade 3 toxicity, two patients (2.6%) developed more than one Grade 3 event and all remaining toxicity events were Grade 2; there were no Grade 4 or 5 events.

Discovery analysis and anti-Tg and anti-TPO candidate autoantibodies

Of the 24 patients used in the discovery pooled serum analysis, melanoma (n=9; 38%) and ovarian cancer (n=5; 21%) comprised the majority. Two patients who were initially assigned to Group IV (+CBR / -toxicity) later developed immune-related hypothy-

Table 1. Characteristics of the 78 patients analyzed in this trial stratified by those who did or did not develop CBR or toxicity to pembrolizumab. Of the entire INSPIRE cohort (n=106), 28 patients did not have paired baseline and pre-cycle 3 serum for analysis and thus were excluded.

Covariates		No. (%) of patients		p-value	No. (%) of patients		p-value
		With CBR (n=24)	Without CBR (n=54)		With toxicity (n=19)	Without toxicity (n=59)	
Sex, female		12 (50)	31 (57)	0.62 ^a	7 (37)	36 (61)	0.11 ^a
Ethnicity, white		20 (83)	44 (83)	>0.99 ^a	18 (95)	46 (79)	0.17 ^a
Age at time of first pembrolizumab infusion, median (range), years		62 (34–82)	58 (21–78)	0.38 ^b	58 (28–73)	61 (21–82)	0.95 ^b
Cohort	A: HNSCC	3 (13)	11 (20)	0.011^a	3 (16)	11 (19)	0.15 ^a
	B: TNBC	1 (4)	11 (20)		1 (5)	11 (19)	
	C: HGSOc	2 (8)	10 (19)		3 (16)	9 (15)	
	D: Melanoma	8 (33)	3 (6)		6 (32)	5 (9)	
	E: Mixed solid tumor	10 (42)	19 (35)		6 (32)	23 (39)	
PD-L1 MPS positive cells $\geq$ 1%		16 (67)	24 (44)	0.088 ^a	11 (58)	29 (49)	0.6 ^a
% PD-L1 MPS positive cells, median (range)		1.5 (0–100)	0 (0–95)	0.029^b	2 (0–100)	0 (0–95)	0.12 ^b

CBR = clinical benefit rate; HGSOc = high-grade serous ovarian carcinoma; HNSCC = head and neck squamous cell carcinoma; MPS = modified percent score; TNBC = triple negative breast cancer.

^a P-value calculated by Fisher Exact Test, unadjusted.

^b P-value calculated by Mann-Whitney, unadjusted.

roidism. There were 14 patients with toxicity in this discovery analysis; the most common events were hypothyroidism (n=6, 43%), rash (n=3, 21%) and pneumonitis (n=3, 21%). In total, four patients developed toxicity before the pre-cycle 3 blood draw. The protein intensities of Tg and TPO identified by immuno-mass spectrometry in the four patient group discovery analysis at both baseline and pre-cycle 3 are shown in [Figure 2a](#) and [Figure 2b](#), respectively.

Of all 78 patients included in this analysis, at baseline, 20 patients had both elevated anti-Tg and anti-TPO titers, three patients had only elevated anti-Tg titers, and 19 had only elevated anti-TPO titers. At pre-cycle 3, 24 patients had both elevated anti-Tg and anti-TPO titers, two patients had only elevated anti-Tg titers, and 18 had only elevated anti-TPO titers. In total, 10 and eight patients developed a significant Δ in anti-Tg and anti-TPO titers, respectively. No patients developed $\geq 50\%$ decrease in titer from baseline to pre-cycle 3. De-identified patient autoantibody titres are available as *Underlying data*³³.

Anti-Tg and anti-TPO antibodies as predictive biomarkers

Anti-Tg ([Table 2](#)) and anti-TPO ([Table 3](#)) titers at baseline, pre-cycle 3 and Δ were analyzed for their association with CBR and toxicity. The analysis of the dichotomized values suggested some associations between anti-Tg and toxicity: Δ was significant in unadjusted (p=0.0024), cohort adjusted (OR=23.8, 95% CI 2.6–221.5, p=0.0053), and multivariable models (OR=17.4, 95% CI 1.8–173.8, p=0.015), suggesting an increased risk for toxicity for patients with a pre- anti-Tg cycle 3 titer $\geq 1.5\times$ from baseline.

Higher levels of anti-Tg pre-cycle 3 also predicted for higher rate of toxicity when adjusting for cohort (OR=4.7, 95% CI 1.2–17.8, p=0.024). Similarly, anti-TPO Δ was significant for predicting toxicity in patients with $\geq 1.5\times$ increase in anti-TPO titers from baseline to pre-cycle 3 in unadjusted (p=0.039) and cohort adjusted (OR=6.1, 95% CI 1.1–32.7, p=0.035) models, although significance was lost in multivariable analysis (p=0.078). Anti-Tg titers at baseline and pre-cycle 3 were not significant for predicting toxicity in multivariate analysis, and anti-TPO baseline and pre-cycle 3 titers were not significant for predicting toxicity in any of the analyses. Further, anti-Tg and anti-TPO titers were not associated with CBR at any time point regardless of statistical approach.

Anti-Tg and anti-TPO titers were also explored as continuous variables for their possible association with CBR and toxicity. The Mann-Whitney test (unadjusted analysis) showed an association of elevated anti-Tg titers with higher risk of toxicity at baseline (p=0.043), pre-cycle 3 (p=0.011) and the difference in titer between these two time points (p=0.001) (*Extended data*³⁰); significance was lost in cohort adjusted and multivariable models. The same type of association was found with anti-TPO: elevated anti-TPO titers were associated with higher risk of toxicity at pre-cycle 3 in the unadjusted model (p=0.045) and difference in titers between baseline and pre-cycle 3 in the cohort adjusted model (p=0.05), although significance was lost in multivariable analysis (*Extended data*³⁰). When analyzed as a continuous variable, anti-Tg and anti-TPO were not predictive of CBR (*Extended data*³⁰).

Figure 1. CONSORT diagram displaying all relevant details regarding the 78 INSPIRE patients used in the autoantibody analysis. Note that patients can develop more than one type of toxicity event. HNSCC, head and neck squamous cell carcinoma; TNBC, triple-negative breast cancer; HGSOc, high-grade serous ovarian carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CBR, clinical benefit rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Figure 2. Protein intensities within the pre-specified four INSPIRE groups. The average baseline and pre-cycle 3 thyroglobulin (Tg) (a) and thyroid peroxidase (TPO) (b) protein intensities. We identified Tg and TPO as candidates during autoantibody target selection from pooled patient sera. CBR, clinical benefit rate.

Table 2. Categorical analysis association of anti-Tg antibodies with CBR and toxicity. Baseline and pre-cycle 3 categories were dichotomized by median titers (10.0 IU/mL) versus > median titers (10.0 IU/mL was anti-Tg titer's lowest limit of instrument detection). Δ was dichotomized using pre-cycle 3 titers $\geq 1.5\times$ baseline titers vs pre-cycle 3 titers $< 1.5\times$ baseline titers. Patients who developed toxicity before pre-cycle 3 blood draw (n=5) were removed from both the CBR and toxicity pre-cycle 3 and Δ analysis.

Event	Time point	Method of dichotomization	Unadjusted			Adjusted for cohort		Multivariable ^a	
			With event – no. (%)	Without event – no. (%)	P value ^b	OR (95% CI)	P value ^c	OR (95% CI)	P value ^d
CBR	Baseline	10.0 IU/mL	17 (71)	38 (70)	> 0.99	0.9 (0.3–2.9)	0.83	0.9 (0.2–3.5)	0.91
		> 10.0 IU/mL	7 (29)	16 (30)					
	Pre-cycle 3	10.0 IU/mL	18 (78)	31 (62)	0.19	0.4 (0.1–1.5)	0.17	0.3 (0.09–1.3)	0.12
		> 10.0 IU/mL	5 (22)	19 (38)					
	Δ	Pre-cycle 3 < 1.5x baseline	20 (87)	43 (86)	> 0.99	0.8 (0.1–4.3)	0.75	0.8 (0.1–5.1)	0.79
		Pre-cycle 3 $\geq 1.5\times$ baseline	3 (13)	7 (14)					
Toxicity	Baseline	10.0 IU/mL	10 (53)	45 (76)	0.08	2.8 (0.9–8.7)	0.076	2.7 (0.6–11.2)	0.18
		> 10.0 IU/mL	9 (47)	14 (24)					
	Pre-cycle 3	10.0 IU/mL	6 (42.9)	43 (73)	0.055	4.7 (1.2–17.8)	0.024	2.6 (0.6–12.3)	0.23
		> 10.0 IU/mL	8 (57)	16 (27)					
	Δ	Pre-cycle 3 < 1.5x baseline	8 (57)	55 (93)	0.0024	23.8 (2.6–221.5)	0.0053	17.4 (1.8–173.8)	0.015
		Pre-cycle 3 $\geq 1.5\times$ baseline	6 (43)	4 (7)					

CBR = clinical benefit rate; CI = confidence intervals; OR = odds ratio.

^aDetermined using propensity scores with cohort as strata and the following covariates: age, gender, ethnicity and PD-L1 status. One patient was removed due to unknown ethnicity.

^bCalculated using Fisher's Exact Test.

^cBased on conditional logistic regression with the cohort as strata.

^dBased on conditional logistic regression with the cohort as strata and adjusted for the propensity scores.

Table 3. Categorical analysis association of anti-TPO antibodies with CBR and toxicity. Baseline and pre-cycle 3 categories were dichotomized by $\leq$ to median titers (10.0 IU/mL) versus $>$ median titers. Δ was dichotomized using pre-cycle 3 titers $\geq 1.5\times$ baseline titers vs pre-cycle 3 titers $< 1.5\times$ baseline titers. Patients who developed toxicity before pre-cycle 3 blood draw (n=5) were removed from both the CBR and toxicity pre-cycle 3 and Δ analysis.

Event	Time point	Method of dichotomization	Unadjusted		P value ^b	Adjusted for cohort		Multivariable ^a	
			With event – no. (%)	Without event – no. (%)		OR (95% CI)	P value ^c	OR (95% CI)	P value ^d
CBR	Baseline	≤ 10.0 IU/mL	11 (46)	28 (52)	0.81	1.3 (0.5–3.6)	0.65	1.0 (0.3–3.1)	0.98
		> 10.0 IU/mL	13 (54)	26 (48)					
	Pre-cycle 3	≤ 10.0 IU/mL	11 (48)	22 (44)	0.80	1.0 (0.3–2.8)	0.97	1.0 (0.3–3.2)	0.94
		> 10.0 IU/mL	12 (52)	28 (56)					
	Δ	Pre-cycle 3 $< 1.5\times$ baseline	21 (91)	44 (88)	> 0.99	0.5 (0.08–3.1)	0.45	0.7 (0.1–4.8)	0.71
		Pre-cycle 3 $\geq 1.5\times$ baseline	2 (9)	6 (12)					
Toxicity	Baseline	≤ 10.0 IU/mL	8 (42)	31 (53)	0.60	1.6 (0.5–4.6)	0.41	1.4 (0.4–4.7)	0.61
		> 10.0 IU/mL	11 (58)	28 (48)					
	Pre-cycle 3	≤ 10.0 IU/mL	4 (29)	29 (49)	0.23	2.7 (0.7–10.3)	0.14	2.3 (0.5–10.2)	0.26
		> 10.0 IU/mL	10 (71)	30 (51)					
	Δ	Pre-cycle 3 $< 1.5\times$ baseline	10 (71)	55 (93)	0.039	6.1 (1.1–32.7)	0.035	5.9 (0.8–42.6)	0.078
		Pre-cycle 3 $\geq 1.5\times$ baseline	4 (29)	4 (7)					

CBR = clinical benefit rate; CI = confidence intervals; OR = odds ratio.

^aDetermined using propensity scores with cohort as strata and the following covariates: age, gender, ethnicity and PD-L1 status. One patient was removed due to unknown ethnicity.

^bCalculated using Fisher's Exact Test.

^cBased on conditional logistic regression with the cohort as strata.

^dBased on conditional logistic regression with the cohort as strata and adjusted for the propensity scores.

Prior to trial enrolment, three patients had pre-existing thyroid disease: two patients with hypothyroidism both had elevated anti-TPO titers at baseline and/or pre-cycle 3 and the one patient with thyroid nodules had non-elevated titers; none of these patients developed either CBR or toxicity on trial. Hypothyroidism development during trial (n=8) was more common among: patients with elevated anti-Tg titers at baseline (75% vs 24%, $p=0.007$), pre-cycle 3 (86% vs 27%, $p=0.0044$) and increase in titers between these two time points (71% vs 7%, $p=0.00026$); and in patients with an increase in anti-TPO titer between baseline and pre-cycle 3 (57% vs 7%, $p=0.0029$). Of the eight patients who developed hypothyroidism, six (75%) had both elevated anti-Tg and anti-TPO antibodies at baseline and pre-cycle 3, one patient (12.5%) developed elevated anti-Tg and anti-TPO titers at pre-cycle 3, and the last patient had non-elevated titers at both time points. Conversely, of the 70 patients who did not develop hypothyroidism, 42 (60%) had elevated anti-Tg and/or anti-TPO titers at baseline and/or pre-cycle 3. There was no statistically significant association of anti-Tg or anti-TPO with the development of non-thyroid toxicities. Of the 11 patients who developed non-thyroidal toxicity, five (46%) had either anti-Tg or anti-TPO titers elevated at baseline or pre-cycle 3.

Anti-Tg and anti-TPO antibodies as prognostic biomarkers

Elevated baseline anti-Tg or anti-TPO titers did not show a significant difference in OS (Figure 3a and Figure 4a, respectively) or PFS (see *Extended data*³⁰). Although elevated pre-cycle 3 anti-Tg titers were not associated with OS (Figure 3b), patients with elevated pre-cycle 3 anti-TPO titers did have a significant difference in OS (23.8 months vs 11.5 months; HR=1.8, 95% CI 1.0–3.2, $p=0.05$) (Figure 4b). Pre-cycle 3 anti-Tg and anti-TPO titers were not associated with PFS (see *Extended data*³⁰). Finally, anti-Tg and anti-TPO Δ was not significant for OS and PFS (see *Extended data*³⁰).

Toxicity analysed as a time-dependent covariate was not associated with OS ($p=0.11$) or PFS ($p=0.47$).

Association of anti-Tg and anti-TPO antibodies with standard prognostic variables

Associations between the candidate autoantibodies were explored as both categorical and continuous variables with the confounding covariates: age, gender, ethnicity and PD-L1 status. White ethnicity was associated with higher anti-Tg titers at baseline (continuous: $p=0.048$) and pre-cycle 3 (categorical: $p=0.05$;

Figure 3. Kaplan-Meier overall survival analysis using anti-Tg titers. Patients were dichotomized based upon anti-thyroglobulin (Tg) titers greater than, or equal to, median (10.0 IU/mL) at (a) baseline and (b) pre-cycle 3. B, baseline; C3, pre-cycle 3; CI, confidence interval; HR, hazard ratio.

Figure 4. Kaplan-Meier overall survival analysis using anti-thyroid peroxidase (TPO) titers. Patients were dichotomized based upon anti-TPO levels greater than median (10.0 IU/mL) or ≤ median at (a) baseline and (b) pre-cycle 3. P-values are unadjusted and calculated using the Wald test. B, baseline; C3, pre-cycle 3; CI, confidence interval; HR, hazard ratio.

continuous: $p=0.031$) (see *Extended data*³⁰). The remaining covariates did not exhibit any association with the autoantibodies (see *Extended data*³⁰). The Spearman correlation coefficients calculated between the autoantibodies with age and PD-L1 as continuous variables were very small ranging between -0.167 and 0.14, suggesting lack of association between these variables (see *Extended data*³⁰).

Discussion

To our knowledge, this is the first study to perform an extensive autoantibody analysis in the pre- and post-pembrolizumab sera of patients with mixed solid tumors, and then determine the association of candidate autoantibodies with clinical benefit and toxicity. Our study suggested that patients with an increase in anti-Tg or anti-TPO titers from baseline to pre-cycle 3 are associated with significant toxicity in unadjusted and cohort-adjusted

models, and the anti-Tg increase is also significant for toxicity in multivariable models. Hypothyroidism was observed in 10% in our cohort, which is consistent with the 6.5–7.9% incidence reported in an ICB meta-analysis³⁸, and accounted for 42% of all our toxicity events. Nearly half of our patients with non-thyroid toxicity had elevated anti-Tg and/or anti-TPO titers; however, we were unable to demonstrate an association of these antibodies with non-thyroid toxicity. A recent retrospective analysis of non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 monotherapy demonstrated similar results: pre-treatment anti-Tg and/or anti-TPO antibodies were associated with the development of immune-related hypothyroidism, but not other irAEs³⁹. While antibodies for multiple autoimmune illnesses can develop simultaneously^{40–42}, our analysis only chose the candidate with the largest number of identified peptides and a related candidate, and thus any non-thyroidal autoantibodies

that may have been present were not analyzed. Future work assessing a larger spectrum of autoantibodies to create a biomarker signature will aid in addressing this issue.

Herein we found an association between elevated pre-cycle 3 anti-TPO antibodies with OS. This is in keeping with the NSCLC study that showed baseline autoantibodies (including anti-Tg and anti-TPO) were associated with improved PFS and disease control rate during treatment with anti-PD-1 monotherapy³⁹. However, given our lack of association between anti-TPO with CBR and PFS, and baseline and Δ anti-TPO with OS, caution must be used in interpreting this result. Future trials enriching for specific disease sites will help elucidate the role autoantibodies may play as a prognostic and predictive biomarker to ICB.

The association of irAEs with increased survival or response to ICB has been found in melanoma⁴³ and NSCLC⁴⁴ studies using statistical methods to prevent bias from the time-dependence of both predictor and outcome variables^{45,46}. The analysis of toxicity as a time-dependent covariate did not corroborate this principle in our prospective trial of multiple histologies. If benefit is most likely procured from patients with toxicity events, then astute monitoring and early recognition of irAEs is paramount to control these toxicity events and prevent early treatment discontinuation.

Not surprisingly, our association of baseline and on treatment anti-Tg or anti-TPO antibodies with the development of hypothyroidism is supported by other anti-PD-1 studies^{20,21,39,47}. Interestingly, it appears cancer patients harbor higher rates of pre-existent autoantibodies: our pre-treatment combined anti-Tg and anti-TPO rate of 54%, and published rates of NSCLC patient pre-treatment rheumatoid factor and antinuclear antibody rates of 28% and 35%, respectively³⁹, are higher than the general population rates of anti-Tg (11%), anti-TPO (13%), rheumatoid factor (5–25%) and antinuclear antibodies (27%)^{48–50}. While the development of tumor-associated autoantibodies to aberrant protein structures¹² has undergone considerable biomarker investigation^{51–55}, the mechanism of cancer patients developing autoantibodies to endogenous proteins and their biomarker potential is less clear.

The increase in anti-thyroid antibody titers shortly after treatment initiation, or the development of new anti-thyroid antibodies following treatment, points to a possible unmasking of latent autoimmunity by pembrolizumab. Patients with pre-existing latent autoimmunity characterized by increased autoantibody titers may be at higher risk of developing toxicity from ICB. We suggest future prospective studies of other autoimmune markers at baseline are evaluated in patients treated with ICB to further elucidate a mechanism for this effect.

Our study showed that patients can still develop hypothyroidism without the presence of anti-Tg and anti-TPO antibodies. Our reported rate on study of elevated anti-Tg and/or anti-TPO antibodies among those who developed hypothyroidism was 88%, which is comparable to the rates of elevated anti-Tg and anti-TPO antibodies in patients with chronic autoimmune thyroiditis within the general population (70–80% and 90–95%, respectively⁵⁶). The

paucity of anti-Tg and anti-TPO antibodies in those who develop autoimmune primary hypothyroidism implies a non-humoral pathway. As observed in chronic autoimmune thyroiditis, these hypothyroidism events may be secondary to: reduced number and/or function of immune regulatory suppressor cells (e.g. CD4+CD25+)^{57,58}; the large diversity of the third complementarity-determining region of T-cell surface antigen receptors creating increased propensity of attacking thyroid tissue⁵⁹; from Th1 cytotoxic T-cell apoptotic destruction of thyroid tissue⁶⁰; or loss of self-tolerance⁶¹ by direct interaction of anti-PD1-/L1 agents with PD-L1/L2 expressed on normal thyroid tissue⁶². Since Th1 lymphocytes secrete interleukin-2, interferon gamma, and tumor necrosis factor-beta⁶³, evaluation of these cytokines may help elucidate the role of these cells in anti-PD-1-induced non-humoral hypothyroidism.

This study has several limitations. This was a proof-of-concept study designed to screen for candidate autoantibody targets in a mixed solid tumor cohort. Our proteome was not comprehensive and may have missed potential targets during autoantibody candidate selection. During the candidate selection, the status of two patients changed due to the late development of significant toxicity events and four patients developed a toxicity event before the pre-cycle 3 blood draw, possibly skewing these preliminary results. Since the change in peptide quantity was used to select the candidates, the act of pooling serum samples among the four different patient groups may have diluted autoantibody targets present in low titers. Further, the candidates were selected based on peptide number increases from pre- to post-pembrolizumab, thus excluding possible candidates from baseline titers alone. Our study with mixed histologies, each in small numbers, creates a challenge in interpreting the CBR results. In total, 26 patients came off trial prior to pre-cycle 3 blood processing and were removed from the autoantibody analysis. This incomplete patient representation may bias event outcomes and distort the predictive/prognostic potential of the candidate autoantibodies. Since new irAEs from PD1 inhibition can occur many months after starting treatment⁴³, and onset of hypothyroidism post-PD-1 initiation can range from 0.7 weeks to 19 months⁵, there is the possibility that ongoing patient follow up will yield new toxicity events. This is especially pertinent to the patients who developed non-thyroidal toxicity who have anti-thyroid antibodies present. The small number patients analyzed and limited number of response and toxicity events yields low statistical power and may give spurious results. Ultimately, our findings require further validation in an independent prospective dataset, with adequate sample size to detect histology-specific effects on survival.

Conclusions

We have shown an association of an increase in anti-Tg and anti-TPO titers between baseline at pre-cycle 3 pembrolizumab with toxicity, elevated pre-cycle 3 anti-Tg with toxicity, and elevated pre-cycle 3 anti-TPO with OS. However, anti-Tg and anti-TPO were unable to predict for non-thyroid toxicity. Future prospective trials evaluating these antibodies, ideally at a time point earlier than pre-cycle 3 of pembrolizumab or with other ICB agents, are needed to validate this finding. Enriching for

patients with a single disease site will aid in determining their association with CBR. If successful, this will yield the first data for a minimally invasive, blood-based predictive biomarker to identify which patients derive benefit and/or toxicity from pembrolizumab, sparing unnecessary financial burden and delays to more appropriate care.

Data availability

Underlying data

Figshare: Autoantibody dataset.xlsx. <https://doi.org/10.6084/m9.figshare.12149598>³³.

This file contains the autoantibody dataset generated and assessed during this study, including patient outcomes, autoantibody titers and mass spectrometry data.

Extended data

Figshare: Extended data.docx. <https://doi.org/10.6084/m9.figshare.12149601.v1>³⁰.

This extended data file contains the following information:

- Concentration of protein in various tissue lysates used for autoantibody binding.
- Autoantibody immuno-mass spectrometry methods.
- Immunohistochemistry methods and MPS calculation.
- Beeswarm plots showing anti-Tg antibody titers in those with or without toxicity from pembrolizumab.
- Statistics of anti-Tg and anti-TPO antibody as continuous variables and their association with CBR and toxicity.
- Beeswarm plots showing anti-TPO antibody titers in patients with and without toxicity to pembrolizumab.
- Beeswarm plots showing anti-Tg antibody titers in those with or without CBR from pembrolizumab.
- Beeswarm plots showing anti-TPO antibody titers in those with or without CBR from pembrolizumab.
- Kaplan-Meier PFS analysis using baseline and pre-cycle 3 anti-Tg.
- Kaplan-Meier PFS analysis using baseline and pre-cycle 3 anti-TPO.
- Kaplan-Meier analysis using Δ anti-Tg.
- Kaplan-Meier analysis using Δ anti-TPO.
- Analysis of covariate ethnicity with anti-Tg and anti-TPO titers as a categorical variable.
- Analysis of covariate ethnicity with anti-Tg and anti-TPO titers as continuous variables.
- Analysis of covariate gender with anti-Tg and anti-TPO titers as categorical variables.
- Analysis of covariate gender with anti-Tg and anti-TPO titers as continuous variables.
- Analysis of covariate PD-L1 MPS percentage as a categorical variable with anti-Tg and anti-TPO titers as categorical variables.
- Analysis of covariate PD-L1 MPS percentage as a continuous variable with anti-Tg and anti-TPO titers as categorical variables.
- Analysis of covariate PD-L1 MPS as a categorical variable and anti-Tg and anti-TPO titers as continuous variables.
- Analysis of covariate age as a continuous variable with anti-Tg and anti-TPO titers as categorical variables.
- Analysis of standard prognostic variables age and PD-L1 MPS with anti-Tg and anti-TPO titers, all as continuous variables.

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Author contributions

MI, MM, LLS and EPD wrote the paper. MM, AS, IB, IP and EPD conducted the experiments. MI, MM, LLS and EPD analyzed the data. MI, ARH, PLB, SL, AS, AAR and LLS are clinicians involved with enrolling patients. MP provided statistical support. All authors read the paper and concur with the submission. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank the patients and their families for their participation.

References

1. Farkona S, Diamandis EP, Blasutig IM: **Cancer immunotherapy: the beginning of the end of cancer?** *BMC Med.* 2016; **14**: 73. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Cully M: **Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy.** *Nat Rev Drug Discov.* 2015; **14**(6): 374–5. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Sunshine J, Taube JM: **PD-1/PD-L1 inhibitors.** *Curr Opin Pharmacol.* 2015; **23**: 32–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Larkin J, Chiarion-Sileni V, Gonzalez R, *et al.*: **Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.** *N Engl J Med.* 2015; **373**(1): 23–34. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Villadolid J, Amin A: **Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.** *Transl Lung Cancer Res.* 2015; **4**(5): 560–75. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Weber JS, D'Angelo SP, Minor D, *et al.*: **Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.**

- Lancet Oncol.* 2015; **16**(4): 375–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Robert C, Schachter J, Long GV, *et al.*: **Pembrolizumab versus Ipilimumab in Advanced Melanoma.** *N Engl J Med.* 2015; **372**(26): 2521–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
 8. Brahmer J, Reckamp KL, Baas P, *et al.*: **Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.** *N Engl J Med.* 2015; **373**(2): 123–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 9. Gibney GT, Weiner LM, Atkins MB: **Predictive biomarkers for checkpoint inhibitor-based immunotherapy.** *Lancet Oncol.* 2016; **17**(12): e542–e51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 10. Yu Z, Tan Z, Lee BK, *et al.*: **Antigen spreading-induced CD8⁺T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.** *Oncotarget.* 2015; **6**(32): 32426–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 11. Miyauchi K, Tsuchikawa T, Wada M, *et al.*: **Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination.** *Immunotherapy.* 2016; **8**(5): 527–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. Caron M, Choquet-Kastylevsky G, Joubert-Caron R: **Cancer immunomics using autoantibody signatures for biomarker discovery.** *Mol Cell Proteomics.* 2007; **6**(7): 1115–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 13. Murphy MA, O'Leary JJ, Cahill DJ: **Assessment of the humoral immune response to cancer.** *J Proteomics.* 2012; **75**(15): 4573–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Tan HT, Low J, Lim SG, *et al.*: **Serum autoantibodies as biomarkers for early cancer detection.** *FEBS J.* 2009; **276**(23): 6880–904.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Baldwin RW: **Tumour-specific immunity against spontaneous rat tumours.** *Int J Cancer.* 1966; **1**(3): 257–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Tan EM: **Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.** *J Clin Invest.* 2001; **108**(10): 1411–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 17. Kwek SS, Dao V, Roy R, *et al.*: **Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.** *J Immunol.* 2012; **189**(7): 3759–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Da Gama Duarte J, Parakh S, Andrews MC, *et al.*: **Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intravesical *Bacillus Calmette-Guérin* followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.** *Front Immunol.* 2018; **9**: 411.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 19. Gowen MF, Giles KM, Simpson D, *et al.*: **Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.** *J Transl Med.* 2018; **16**(1): 82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 20. Maekura T, Naito M, Tahara M, *et al.*: **Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.** *In Vivo.* 2017; **31**(5): 1035–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. de Filette J, Jansen Y, Schreuer M, *et al.*: **Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.** *J Clin Endocrinol Metab.* 2016; **101**(11): 4431–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Meroni PL, Biggoggero M, Pierangeli SS, *et al.*: **Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases.** *Nat Rev Rheumatol.* 2014; **10**(1): 35–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Anderson KS, LaBaer J: **The sentinel within: exploiting the immune system for cancer biomarkers.** *J Proteome Res.* 2005; **4**(4): 1123–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Liu J, Xing X, Huang H, *et al.*: **Identification of antigenic proteins associated with trichloroethylene-induced autoimmune disease by serological proteome analysis.** *Toxicol Appl Pharmacol.* 2009; **240**(3): 393–400.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Klade CS, Voss T, Krystek E, *et al.*: **Identification of tumor antigens in renal cell carcinoma by serological proteome analysis.** *Proteomics.* 2001; **1**(7): 890–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Massa O, Alessio M, Russo L, *et al.*: **Serological Proteome Analysis (SERPA) as a tool for the identification of new candidate autoantigens in type 1 diabetes.** *J Proteomics.* 2013; **82**: 263–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Eisenhauer EA, Therasse P, Bogaerts J, *et al.*: **New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).** *Eur J Cancer.* 2009; **45**(2): 228–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. **Common Terminology Criteria for Adverse Events (CTCAE) v4.03.** 2010.
[Reference Source](#)
 29. Champiat S, Lambotte O, Barreau E, *et al.*: **Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.** *Ann Oncol.* 2016; **27**(4): 559–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Iafolla M, Music M, Soosaipillai A, *et al.*: **Extended data.docx. figshare.** Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12149601.v1>
 31. Music M, Soosaipillai A, Batruch I, *et al.*: **A proteome-wide immuno-mass spectrometric identification of serum autoantibodies.** *Clin Proteomics.* 2019; **16**: 25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Ohyama K, Ueki Y, Kawakami A, *et al.*: **Immune complexome analysis of serum and its application in screening for immune complex antigens in rheumatoid arthritis.** *Clin Chem.* 2011; **57**(6): 905–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Iafolla M, Music M, Soosaipillai A, *et al.*: **Autoantibody dataset.xlsx. figshare.** Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12149598>
 34. Cobas: **Anti-Tg.** 2019.
[Reference Source](#)
 35. Cobas: **Elecsys Anti-TPO.** 2019.
[Reference Source](#)
 36. Jensen E, Petersen PH, Blaabjerg O, *et al.*: **Biological variation of thyroid autoantibodies and thyroglobulin.** *Clin Chem Lab Med.* 2007; **45**(8): 1058–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Clouthier DL, Lien SC, Yang SYC, *et al.*: **An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).** *J Immunother Cancer.* 2019; **7**(1): 72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Barroso-Sousa R, Barry WT, Garrido-Castro AC, *et al.*: **Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.** *JAMA Oncol.* 2018; **4**(2): 173–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Toi Y, Sugawara S, Sugisaka J, *et al.*: **Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.** *JAMA Oncol.* 2019; **5**(3): 376–383.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Teufel A, Weinmann A, Kahaly GJ, *et al.*: **Concurrent autoimmune diseases in patients with autoimmune hepatitis.** *J Clin Gastroenterol.* 2010; **44**(3): 208–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Rodriguez-Reyna TS, Alarcon-Segovia D: **Overlap syndromes in the context of shared autoimmunity.** *Autoimmunity.* 2005; **38**(3): 219–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Frohlich E, Wahl R: **Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases.** *Front Immunol.* 2017; **8**: 521.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Weber JS, Hodi FS, Wolchok JD, *et al.*: **Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.** *J Clin Oncol.* 2017; **35**(7): 785–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Haratani K, Hayashi H, Chiba Y, *et al.*: **Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.** *JAMA Oncol.* 2018; **4**(3): 374–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Probert KJ, Anderson JR: **Assessing the effect of toxicity on prognosis: methods of analysis and interpretation.** *J Clin Oncol.* 1988; **6**(5): 868–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Anderson JR, Cain KC, Gelber RD: **Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.** *J Clin Oncol.* 2008; **26**(24): 3913–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Osorio JC, Ni A, Chaff JE, *et al.*: **Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.** *Ann Oncol.* 2017; **28**(3): 583–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Hollowell JG, Staehling NW, Flanders WD, *et al.*: **Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).** *J Clin Endocrinol Metab.* 2002; **87**(2): 489–99.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Kumagai S, Hayashi N: **Immunofluorescence—still the 'gold standard' in ANA testing?** *Scand J Clin Lab Invest Suppl.* 2001; **235**: 77–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Shmerling RH, Delbanco TL: **The rheumatoid factor: an analysis of clinical utility.** *Am J Med.* 1991; **91**(5): 528–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Chapman CJ, Thorpe AJ, Murray A, *et al.*: **Immunobiomarkers in small cell lung cancer: potential early cancer signals.** *Clin Cancer Res.* 2011; **17**(6): 1474–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Zayakin P, Ancans G, Silina K, *et al.*: **Tumor-associated autoantibody signature**

- for the early detection of gastric cancer. *Int J Cancer*. 2013; **132**(1): 137–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Anderson KS, Sibani S, Wallstrom G, *et al.*: **Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer.** *J Proteome Res*. 2011; **10**(1): 85–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Anderson KS, Cramer DW, Sibani S, *et al.*: **Autoantibody Signature for the Serologic Detection of Ovarian Cancer.** *J Proteome Res*. 2015; **14**(1): 578–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Stockert E, Jager E, Chen YT, *et al.*: **A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.** *J Exp Med*. 1998; **187**(8): 1349–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. Carvalho GA, Perez CL, Ward LS: **The clinical use of thyroid function tests.** *Arq Bras Endocrinol Metabol*. 2013; **57**(3): 193–204.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. McLachlan SM, Nagayama Y, Pichurin PN, *et al.*: **The link between Graves' disease and Hashimoto's thyroiditis: a role for regulatory T cells.** *Endocrinology*. 2007; **148**(12): 5724–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Glick AB, Wodzinski A, Fu P, *et al.*: **Impairment of regulatory T-cell function in autoimmune thyroid disease.** *Thyroid*. 2013; **23**(7): 871–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Davies TF, Concepcion ES, Ben-Nun A, *et al.*: **T-cell receptor V gene use in autoimmune thyroid disease: direct assessment by thyroid aspiration.** *J Clin Endocrinol Metab*. 1993; **76**(3): 660–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Liblau RS, Singer SM, McDevitt HO: **Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases.** *Immunol Today*. 1995; **16**(1): 34–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. McLachlan SM, Rapoport B: **Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.** *Endocr Rev*. 2014; **35**(1): 59–105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Yamauchi I, Sakane Y, Fukuda Y, *et al.*: **Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.** *Thyroid*. 2017; **27**(7): 894–901.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Mosmann TR, Coffman RL: **TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.** *Annu Rev Immunol*. 1989; **7**: 145–73.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 30 November 2020

<https://doi.org/10.5256/f1000research.25082.r75094>

© 2020 Salvatore F et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Francesco Salvatore

CEINGE-Biotecnologie Avanzate s.c.ar.l., Naples, Italy

Domenico Salvatore

Section of Endocrinology, School of Medicine, University of Naples Federico II, Naples, Italy

Porcelli Tommaso

Section of Endocrinology, School of Medicine, University of Naples Federico II, Naples, Italy

The aim of this work by Music *et al.* was to identify biomarkers able to predict the clinical benefit and the risk of irAEs in patients treated with pembrolizumab. In a discovery analysis, the authors found anti-Tg Ab to be significantly increased by pembrolizumab. Therefore, anti-thyroid Ab (i.e., anti-Tg and anti-TPO Abs) were evaluated as predictive biomarkers of tumor response and treatment toxicity in 78 patients treated with pembrolizumab for different tumor types. The aim of the paper appears highly interesting. The authors clearly show that patients with an increase in baseline anti-Tg and anti-TPO titers after 7 weeks of treatment presented higher rate of toxicity in response to pembrolizumab. Moreover, the authors found an association between anti-TPO titer and overall survival, although without benefit in progression-free survival.

Interestingly, 50% of patients that developed hypothyroidism as irAEs were treated with pembrolizumab for a melanoma cancer (i.e. 14% of enrolled patients). Moreover, as shown in table 1, the melanoma group presented the highest rate of patients with clinical benefit rate (CBR) (8/11, 73%) and with toxicity (6/11, 55%). Conversely, other cancers showed very different responses. For example, the triple negative breast cancer presented no cases of hypothyroidism, a low CBR (1/12, 8%) and a low toxicity (1/12, 8%). Accordingly, 6/11 of melanoma patients presented baseline thyroid-Ab alterations and 4/11 presented increase in thyroid-Ab after treatment. I would have suggested to comment in the discussion the strong association between anti-thyroid Ab and CBR/toxicity in melanoma patients.

The cutoff to define auto-Ab elevation was set at 10.0 IU/ml. As shown in the "Autoantibody dataset" tables (ref 33), in 4 patients considered with elevated basal Tg-Ab, the Ab titer was <10.9 IU/ml (in one case was 10.06 IU/ml) and in 3 of these 4 patients there was no increase at pre-cycle 3 measurement. Similarly, 4 patients from the group with elevated pre-cycle 3 TPO-Ab presented

only slightly elevated values (in 2 cases, 10.02 UI/ml). I'm not sure that values of 10.02 IU/ml can be considered as positive, especially if no increase (or a decrease) was observed after treatment. This is important because the reported association between overall survival and elevated pre-cycle 3 anti-TPO Ab is based on these values. I would have suggested to specify in the "Methods" section if serum anti-Ab measurement were repeated for confirmation and if the reported values are a mean value of more measurements.

In Figure 1, in the "outcomes" boxes, the reasons for stopping treatment include both clinical progression and RECIST progression. I would have specified in the "Methods" section which are the criteria for the definition of "clinical progression" and when/why this parameter is chosen instead of RECIST progression to decide for the treatment stop.

In conclusion this is an highly interesting paper, the topic of this study is interesting and the work provides new insight into the field. This proof of concept paper has the additional merit to allow other cohorts of patients to be enrolled and therefore extend the casistics.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Reviewer Francesco Salvatore: pathophysiology and diseases; Reviewers Tommaso Porcelli and Domenico Salvatore: thyroid physiology

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 07 September 2020

<https://doi.org/10.5256/f1000research.25082.r69349>

© 2020 Sykiotis G. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gerasimos Sykiotis

Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital & University of Lausanne, Lausanne, Switzerland

The manuscript is fully well summarized in its abstract, hence there is no need to provide a separate summary here. I recommend to revise the text to address the following comments:

1. The main irAE in the cohort was hypothyroidism. It is then not surprising that the main autoantibodies identified were thyroid-specific proteins, and actually they were “the usual suspects”. In the Discussion, it is mentioned that new insights might be obtained by analyzing cohorts homogeneous as to the primary tumor site. But is there any evidence that the irAE profile depends on the primary tumor site? If so, then it should be cited in support. If not, then this statement should be revised. In either case, it may be more productive to profile (sub)cohorts homogeneous as to the type of irAE(s), rather than the primary tumor site.
2. On the one hand, the analyses shown in Table 2 show no association between anti-Tg antibody levels at baseline and toxicity. On the other hand, the first paragraph on page 9 mentions that hypothyroidism development during treatment was more common among patients with elevated anti-Tg titers at baseline. These two statements appear contradictory, and I would recommend to address and explain this directly in the Discussion. For example, is it because the “toxicity” assessed in Table 2 includes all irAEs?
3. In the second paragraph of page 9, it is mentioned that 60% of patients who did not develop hypothyroidism had elevated anti-Tg or anti-TPO antibody titers at baseline and/or pre-cycle 3. This % is quite high. I recommend that the authors mention specifically the % of patients with positive antibodies at baseline (this is actually done in the Discussion, but for the overall cohort, not specifically for the patients who did not develop hypothyroidism). Also, statistics aside, it appears intuitive to a clinician that if the % of positivity at baseline is so high among patients who do not develop hypothyroidism during treatment, then the predictive value of this baseline assessment will be very low for any given individual patient. I think that this merits a mention.
4. I recommend to address whether patients with positive/elevated anti-Tg or anti-TPO antibodies at baseline were more likely to show an increase of these titers during treatment.
5. Were any patients with pre-existing thyroid disease included in the discovery cohort (top of text in page 9)?

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Thyroid physiology, pathophysiology and disease.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research